Skip to main content
SpringerLink
Log in

Carbon 11-choline positron emission tomography/computed tomography and palliative local therapy for castration-resistant prostate cancer

  • Urology - Original Paper
  • Published:
International Urology and Nephrology Aims and scope Submit manuscript

Abstract

Purpose

Carbon 11-choline positron emission tomography/computed tomography (11C-choline PET/CT) and subsequent local therapy for oligometastatic prostate cancer have been reported to be effective, but their effectiveness in castration-resistant prostate cancer (CRPC) remains unclear. Here, we evaluated the findings of 11C-choline PET/CT in CRPC patients and the efficacy of local treatments in correspondence of the pathologic choline uptake.

Methods

We collected 12 cases of CRPC patients who underwent 11C-choline PET/CT between 2014 and 2016. The outcomes assessed included age, the prostate-specific antigen (PSA) value, the findings of 11C-choline PET/CT, the subsequent treatments, the PSA response following the treatments, and the progression-free survival (PFS).

Results

Seven of 12 cases (median PSA, 3.29 ng/mL) had local prostate cancer and/or one or two metastatic lesions detected by the choline PET/CT. These localized lesions were treated with radiotherapy or lymphadenectomy. PSA decreased in all the seven cases and median PSA response was 86% (range, 23–100%). Median PFS was 8.5 months (range, 2.8–25.3 months). The other five cases (median PSA, 7.41 ng/mL) had multiple metastases and systemic therapies were continued in those cases.

Conclusions

11C-choline PET/CT and the correspondent local treatments may play an important role in the treatment sequence of CRPC in selected patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Siegel RL, Miller KD, Jemal A (2019) Cancer statistics, 2019. CA Cancer J Clin 69:7–34

    Article  Google Scholar 

  2. Parker CC, James ND, Brawley CD, Clarke NW, Hoyle AP, Ali A et al (2018) Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. Lancet 392:2353–2366

    Article  Google Scholar 

  3. Ost P, Bossi A, Decaestecker K, De Meerleer G, Giannarini G, Karnes RJ et al (2015) Metastasis-directed therapy of regional and distant recurrences after curative treatment of prostate cancer: a systematic review of the literature. Eur Urol 67:852–863

    Article  Google Scholar 

  4. Sasaki T, Nakamura K, Ogawa K, Onishi H, Okamoto A, Koizumi M et al (2009) Radiotherapy for patients with localized hormone-refractory prostate cancer: results of the patterns of care study in Japan. BJU Int 104:1462–1466

    Article  Google Scholar 

  5. Pascoe AC, Sundar S (2012) Prostate radiation in non-metastatic castrate refractory prostate cancer provides an interesting insight into biology of prostate cancer. Radiat Oncol 7:43

    Article  Google Scholar 

  6. Fanti S, Minozzi S, Castellucci P, Balduzzi S, Herrmann K, Krause BJ et al (2016) PET/CT with (11)C-choline for evaluation of prostate cancer patients with biochemical recurrence: meta-analysis and critical review of available data. Eur J Nucl Med Mol Imaging 43:55–69

    Article  CAS  Google Scholar 

  7. Evangelista L, Briganti A, Fanti S, Joniau S, Reske S, Schiavina R et al (2016) New clinical indications for (18)F/(11)C-choline, new tracers for positron emission tomography and a promising hybrid device for prostate cancer staging: a systematic review of the literature. Eur Urol 70:161–175

    Article  Google Scholar 

  8. Karnes RJ, Murphy CR, Bergstralh EJ, DiMonte G, Cheville JC, Lowe VJ et al (2015) Salvage lymph node dissection for prostate cancer nodal recurrence detected by 11C-choline positron emission tomography/computerized tomography. J Urol 193:111–116

    Article  Google Scholar 

  9. Picchio M, Berardi G, Fodor A, Busnardo E, Crivellaro C, Giovacchini G et al (2014) (11)C-Choline PET/CT as a guide to radiation treatment planning of lymph-node relapses in prostate cancer patients. Eur J Nucl Med Mol Imaging 41:1270–1279

    Article  CAS  Google Scholar 

  10. De Giorgi U, Caroli P, Scarpi E, Conteduca V, Burgio SL, Menna C et al (2015) (18)F-Fluorocholine PET/CT for early response assessment in patients with metastatic castration-resistant prostate cancer treated with enzalutamide. Eur J Nucl Med Mol Imaging 42:1276–1283

    Article  Google Scholar 

  11. De Giorgi U, Caroli P, Burgio SL, Menna C, Conteduca V, Bianchi E et al (2014) Early outcome prediction on 18F-fluorocholine PET/CT in metastatic castration-resistant prostate cancer patients treated with abiraterone. Oncotarget 5:12448–12458

    Article  Google Scholar 

  12. Ceci F, Castellucci P, Graziani T, Schiavina R, Renzi R, Borghesi M et al (2016) (11)C–Choline PET/CT in castration-resistant prostate cancer patients treated with docetaxel. Eur J Nucl Med Mol Imaging 43:84–91

    Article  CAS  Google Scholar 

  13. Pasqualetti F, Cocuzza P, Coraggio G, Ferrazza P, Derosa L, Galli L et al (2016) Long-term PSA control with repeated stereotactic body radiotherapy in a patient with oligometastatic castration-resistant prostate cancer. Oncol Res Treat 39:217–220

    Article  Google Scholar 

  14. Pasqualetti F, Panichi M, Sainato A, Matteucci F, Galli L, Cocuzza P et al (2016) [(18)F]Choline PET/CT and stereotactic body radiotherapy on treatment decision making of oligometastatic prostate cancer patients: preliminary results. Radiat Oncol 11:9

    Article  Google Scholar 

  15. Krause BJ, Souvatzoglou M, Tuncel M, Herrmann K, Buck AK, Praus C et al (2008) The detection rate of [11C]choline-PET/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer. Eur J Nucl Med Mol Imaging 35:18–23

    Article  CAS  Google Scholar 

  16. Radwan N, Phillips R, Ross A, Rowe SP, Gorin MA, Antonarakis ES et al (2017) A phase II randomized trial of Observation versus stereotactic ablative radiation for oligometastatic prostate CancEr (ORIOLE). BMC Cancer 17:453

    Article  Google Scholar 

  17. Habl G, Straube C, Schiller K, Duma MN, Oechsner M, Kessel KA et al (2017) Oligometastases from prostate cancer: local treatment with stereotactic body radiotherapy (SBRT). BMC Cancer 17:361

    Article  Google Scholar 

  18. Alonso O, Dos Santos G, García Fontes M, Balter H, Engler H (2018) (68)Ga-PSMA and (11)C-choline comparison using a tri-modality PET/CT-MRI (3.0 T) system with a dedicated shuttle. Eur J Hybrid Imaging 2:9

    Article  Google Scholar 

  19. Schwenck J, Rempp H, Reischl G, Kruck S, Stenzl A, Nikolaou K et al (2017) Comparison of (68)Ga-labelled PSMA-11 and (11)C-choline in the detection of prostate cancer metastases by PET/CT. Eur J Nucl Med Mol Imaging 44:92–101

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We thank Dr. Jimpei Kumagai for collecting data and many advices for study design. This study was supported by a grant from Takeda Pharmaceutical Company Limited.

Author information

Author notes

  1. Keina Nozaki and Taketo Kawai contributed equally to this work.

Authors and Affiliations

  1. Department of Urology, Center Hospital of National Center for Global Health and Medicine, 1-21-1, Toyama, Shinjuku-ku, Tokyo, 1628655, Japan

    Keina Nozaki, Tetsuya Fujimura, Takahiro Oshina & Atsuko Takahashi

  2. Department of Urology, Graduate School of Medicine, The University of Tokyo, 7-3-1, Hongo, Bunkyo-ku, Tokyo, 1138655, Japan

    Taketo Kawai, Hotaka Matsui, Taro Teshima, Yusuke Sato, Daisuke Yamada & Haruki Kume

  3. Department of Urology, Jichi Medical University, 3311-1, Yakushiji, Shimotsuke-shi, Tochigi-ken, 3290498, Japan

    Tetsuya Fujimura

  4. Department of Urology, Tokyo Metropolitan Tama Medical Center, 2-8-29, Musashidai, Fuchu-shi, Tokyo, 1838524, Japan

    Takeshi Azuma

  5. Department of Radiology, Division of Nuclear Medicine, Center Hospital of National Center for Global Health and Medicine, 1-21-1, Toyama, Shinjuku-ku, Tokyo, 1628655, Japan

    Masatoshi Hotta, Kazuhiko Nakajima & Ryogo Minamimoto

  6. Department of Radiation Oncology, Center Hospital of National Center for Global Health and Medicine, 1-21-1, Toyama, Shinjuku-ku, Tokyo, 1628655, Japan

    Hidetsugu Nakayama

Authors
  1. Keina Nozaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Taketo Kawai
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Tetsuya Fujimura
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hotaka Matsui
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Taro Teshima
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Takahiro Oshina
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Atsuko Takahashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Yusuke Sato
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Daisuke Yamada
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Takeshi Azuma
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Masatoshi Hotta
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Kazuhiko Nakajima
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Hidetsugu Nakayama
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Ryogo Minamimoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Haruki Kume
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Taketo Kawai.

Ethics declarations

Conflict of interest

The authors have no conflicts of interest to declare.

Ethical approval

This study was approved by the ethical committee of National Center for Global Health and Medicine (authorization number: 1552). All of the participants gave their written informed consent.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Nozaki, K., Kawai, T., Fujimura, T. et al. Carbon 11-choline positron emission tomography/computed tomography and palliative local therapy for castration-resistant prostate cancer. Int Urol Nephrol 51, 1763–1769 (2019). https://doi.org/10.1007/s11255-019-02233-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11255-019-02233-y

Keywords

Search

Navigation